Head & Neck Cancers

The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses natural killer-directed therapy in head and neck cancer.

Pembrolizumab (Keytruda) did not meet the primary endpoint of overall survival in the phase III KEYNOTE-040 trial in patients with previously-treated recurrent or metastatic head and neck squamous cell carcinoma.

Joshua Bauml, MD, discusses the current role of immunotherapy in this disease, potential next steps, and unmet needs in HPV-associated head and neck cancer.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy combinations for patients with head and neck cancer.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for patients with head and neck cancer.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses current clinical trials in head and neck cancer.

Jared Weiss, MD, discusses the evolving role of immunotherapy and other promising developments in head and neck cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Ezra Cohen, MD, discusses anti–PD-1/PD-L1 combination regimens in HNSCC, the potential for CAR T-cell therapy, and remaining challenges with immunotherapy in the field.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Following treatment with single-agent nivolumab (Opdivo), patients with head and neck squamous cell carcinoma saw improved or stable quality of life scores.

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses a phase II study investigating induction chemotherapy and transoral surgery for patients with head and neck cancer.

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the treatment for patients with HPV-associated head and neck cancer.